Effects of Anterior Pituitary Adenomas’ Hormones on Glucose Metabolism and Its Clinical Implications

References

• Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl5):v1–v49. doi:10.1093/neuonc/nos218
   PubMedGoogle Scholar
• Pekic S, Stojanovic M, Popovic V. Contemporary issues in the evaluation and management of pituitary adenomas. Minerva Endocrinol. 2015;40(4):307–319.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377–382. doi:10.1111/j.1365-2265.2009.03667.x
   PubMed Web of Science ®Google Scholar
• Fontana E, Gaillard R. Epidémiologie des adénomes hypophysaires : étude dans une agglomération urbaine de suisse[Epidemiology of pituitary adenoma: results of the first Swiss study]. Rev Med Suisse. 2009;5(223):2172–2174. French.
   PubMedGoogle Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16(4):545–553. doi:10.1007/s11102-012-0454-0
   PubMed Web of Science ®Google Scholar
• Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. Am Fam Physician. 2013;88(5):319–327.
   PubMed Web of Science ®Google Scholar
• Tjörnstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171(4):519–526. doi:10.1530/eje-14-0144
   PubMed Web of Science ®Google Scholar
• Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab. 2010;95(9):4268–4275. doi:10.1210/jc.2010-0537
   PubMed Web of Science ®Google Scholar
• Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655–664. doi:10.1530/eje-15-0189
   PubMed Web of Science ®Google Scholar
• Osorio RC, Oh JY, Choudhary N, Lad M, Savastano L, Aghi MK. Pituitary adenomas and cerebrovascular disease: a review on pathophysiology, prevalence, and treatment. Front Endocrinol. 2022;13. doi:10.3389/fendo.2022.1064216
   Web of Science ®Google Scholar
• Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016;27(7):470–483. doi:10.1016/j.tem.2016.04.014
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296(11):589–600. doi:10.1056/nejm197703172961103
   PubMed Web of Science ®Google Scholar
• Koppelman MC, Kurtz DW, Morrish KA, et al. Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab. 1984;59(6):1050–1053. doi:10.1210/jcem-59-6-1050
   PubMed Web of Science ®Google Scholar
• Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002;20(4):365–374. doi:10.1055/s-2002-36709
   PubMed Web of Science ®Google Scholar
• Poon A, McNeill P, Harper A, O’Day J. Patterns of visual loss associated with pituitary macroadenomas. Aust N Z J Ophthalmol. 1995;23(2):107–115. doi:10.1111/j.1442-9071.1995.tb00138.x
   PubMedGoogle Scholar
• Grattan DR. 60 years Of neuroendocrinology: the hypothalamo-prolactin axis. J Endocrinol. 2015;226(2):T101–T122. doi:10.1530/joe-15-0213
   PubMed Web of Science ®Google Scholar
• Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front Endocrinol. 2019;10:327. doi:10.3389/fendo.2019.00327
   PubMed Web of Science ®Google Scholar
• Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225–268. doi:10.1210/edrv.19.3.0334
   PubMed Web of Science ®Google Scholar
• Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15(6):356–365. doi:10.1038/s41574-019-0194-6
   PubMed Web of Science ®Google Scholar
• Perić B, Kruljac I, Šundalić S, et al. Obesity and hypercholesterolemia in patients with prolactinomas: could DHEA-S and growth hormone be the missing link? Endocr Res. 2016;41(3):200–206. doi:10.3109/07435800.2015.1135444
   PubMed Web of Science ®Google Scholar
• Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 1998;48(5):547–553. doi:10.1046/j.1365-2265.1998.00403.x
   PubMed Web of Science ®Google Scholar
• Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14(3):199–207. doi:10.1007/s11102-010-0277-9
   PubMed Web of Science ®Google Scholar
• Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13(2):99–104. doi:10.1007/bf00745135
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard H, Rasio E, Hardy J. 21.Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril. 1986;45(4):572–574.
   PubMed Web of Science ®Google Scholar
• Perez Millan MI, Luque GM, Ramirez MC, et al. 22.Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice. Endocrinology. 2014;155(3):829–839. doi:10.1210/en.2013-1707
   PubMed Web of Science ®Google Scholar
• Ratner LD, Stevens G, Bonaventura MM, et al. 23.Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice. J Endocrinol. 2016;230(1):157–169. doi:10.1530/joe-15-0528
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. 24.Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary. 2009;12(4):330–334. doi:10.1007/s11102-009-0183-1
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. 25.Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26(4):341–346. doi:10.1007/bf03345182
   PubMed Web of Science ®Google Scholar
• Yavuz D, Deyneli O, Akpinar I, et al. 26. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149(3):187–193. doi:10.1530/eje.0.1490187
   PubMed Web of Science ®Google Scholar
• de Oliveira C, de Mattos AB, Biz C, Oyama LM, Ribeiro EB, Do Nascimento CM. 27.High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations. Lipids Health Dis. 2011;10:11. doi:10.1186/1476-511x-10-11
   PubMed Web of Science ®Google Scholar
• Fruebis J, Tsao TS, Javorschi S, et al. 28.Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005–2010. doi:10.1073/pnas.98.4.2005
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, et al. 29.Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–1295. doi:10.1038/nm788
   PubMed Web of Science ®Google Scholar
• de Assunção Alves Rodrigues LF, Campos SM, Miranda PA, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012;44(11):832–838. doi:10.1055/s-0032-1321832
   PubMed Web of Science ®Google Scholar
• Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404–2411. doi:10.1210/jc.2003-030242
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175–1187. doi:10.1007/s00125-004-1448-x
   PubMed Web of Science ®Google Scholar
• Hannon AM, Thompson CJ, Sherlock M. Diabetes in patients with acromegaly. Curr Diab Rep. 2017;17(2):8. doi:10.1007/s11892-017-0838-7
   PubMed Web of Science ®Google Scholar
• Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22–32. doi:10.1007/s11102-016-0772-8
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81–89. doi:10.1007/s11102-013-0471-7
   PubMed Web of Science ®Google Scholar
• Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301–342. doi:10.1210/er.2009-0033
   PubMed Web of Science ®Google Scholar
• Elkeles RS, Wright AD, Lowy C, Fraser TR. Serum-insulin in acromegaly. Lancet. 1969;2(7621):615–618. doi:10.1016/s0140-6736(69)90327-4
   PubMed Web of Science ®Google Scholar
• Javed A, Balagopal PB, Vella A, et al. Association between thyrotropin levels and insulin sensitivity in euthyroid obese adolescents. Thyroid. 2015;25(5):478–484. doi:10.1089/thy.2015.0005
   PubMed Web of Science ®Google Scholar
• Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986;250(3 Pt 1):E269–E273. doi:10.1152/ajpendo.1986.250.3.E269
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. doi:10.1038/nrm1837
   PubMed Web of Science ®Google Scholar
• Del Rincon JP, Iida K, Gaylinn BD, et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 2007;56(6):1638–1646. doi:10.2337/db06-0299
   PubMed Web of Science ®Google Scholar
• Pedersen MH, Svart MV, Lebeck J, et al. Substrate metabolism and insulin sensitivity during fasting in obese human subjects: impact of GH blockade. J Clin Endocrinol Metab. 2017;102(4):1340–1349. doi:10.1210/jc.2016-3835
   PubMed Web of Science ®Google Scholar
• Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177. doi:10.1210/er.2008-0027
   PubMed Web of Science ®Google Scholar
• Hjelholt AJ, Charidemou E, Griffin JL, et al. Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. Diabetologia. 2020;63(12):2641–2653. doi:10.1007/s00125-020-05262-w
   PubMed Web of Science ®Google Scholar
• Al-Massadi O, Parini P, Ferno J, Luquet S, Quinones M. Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system. Rev Endocr Metab Disord. 2022;23(5):919–930. doi:10.1007/s11154-022-09732-x
   PubMed Web of Science ®Google Scholar
• Rogers SA, Miller SB, Hammerman MR. Growth hormone stimulates IGF I gene expression in isolated rat renal collecting duct. Am J Physiol. 1990;259(3 Pt 2):F474–F479. doi:10.1152/ajprenal.1990.259.3.F474
   PubMedGoogle Scholar
• O’Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab. 2002;87(9):4356–4360. doi:10.1210/jc.2002-020343
   PubMed Web of Science ®Google Scholar
• Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45(1):91–100. doi:10.2337/diab.45.1.91
   PubMed Web of Science ®Google Scholar
• Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 1994;93(3):1131–1139. doi:10.1172/jci117065
   PubMed Web of Science ®Google Scholar
• Elahi D, McAloon-Dyke M, Fukagawa NK, et al. Effects of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol. 1993;265(6 Pt 1):E831–E838. doi:10.1152/ajpendo.1993.265.6.E831
   PubMedGoogle Scholar
• Russell-Jones DL, Bates AT, Umpleby AM, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest. 1995;25(6):403–411. doi:10.1111/j.1365-2362.1995.tb01721.x
   PubMed Web of Science ®Google Scholar
• Bondy C, Werner H, Roberts CT, LeRoith D. Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience. 1992;46(4):909–923. doi:10.1016/0306-4522(92)90193-6
   PubMed Web of Science ®Google Scholar
• Muzumdar RH, Ma X, Fishman S, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006;55(10):2788–2796. doi:10.2337/db06-0318
   PubMed Web of Science ®Google Scholar
• Fujita S, Honda K, Yamaguchi M, Fukuzo S, Saneyasu T, Kamisoyama H. Role of insulin-like growth factor-1 in the central regulation of feeding behavior in chicks. J Poult Sci. 2019;56(4):270–276. doi:10.2141/jpsa.0180127
   PubMed Web of Science ®Google Scholar
• Choi YM, Kim MK, Kwak MK, Kim D, Hong EG. Association between thyroid hormones and insulin resistance indices based on the Korean National Health and Nutrition Examination Survey. Sci Rep. 2021;11(1):21738. doi:10.1038/s41598-021-01101-z
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294–302. doi:10.1007/s11102-012-0420-x
   PubMed Web of Science ®Google Scholar
• Sanders K, Kooistra HS, Galac S. Treating canine Cushing’s syndrome: current options and future prospects. Vet J. 2018;241:42–51. doi:10.1016/j.tvjl.2018.09.014
   PubMed Web of Science ®Google Scholar
• Barbot M, Ceccato F, Scaroni C. Diabetes mellitus secondary to Cushing’s disease. Front Endocrinol. 2018;9:284. doi:10.3389/fendo.2018.00284
   PubMed Web of Science ®Google Scholar
• Scaroni C, Zilio M, Foti M, Boscaro M. Glucose Metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. Endocr Rev. 2017;38(3):189–219. doi:10.1210/er.2016-1105
   PubMed Web of Science ®Google Scholar
• Tanabe H, Yokota K, Shibata N, Satoh T, Watari J, Kohgo Y. Alcohol consumption as a major risk factor in the development of early esophageal cancer in patients with head and neck cancer. Intern Med. 2001;40(8):692–696. doi:10.2169/internalmedicine.40.692
   PubMed Web of Science ®Google Scholar
• Agzarian J, Visscher SL, Knight AW, et al. The cost burden of clinically significant esophageal anastomotic leaks-a steep price to pay. J Thorac Cardiovasc Surg. 2019;157(5):2086–2092. doi:10.1016/j.jtcvs.2018.10.137
   PubMed Web of Science ®Google Scholar
• Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13(10):572–587. doi:10.1038/nrendo.2017.80
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22. doi:10.1172/jci77812
   PubMed Web of Science ®Google Scholar
• Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest. 1993;92(4):2065–2072. doi:10.1172/jci116803
   PubMed Web of Science ®Google Scholar
• Chen TC, Kuo T, Dandan M, et al. The role of striated muscle Pik3r1 in glucose and protein metabolism following chronic glucocorticoid exposure. J Biol Chem. 2021;296:100395. doi:10.1016/j.jbc.2021.100395
   PubMed Web of Science ®Google Scholar
• Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998;47(1):3–6. doi:10.1016/s0026-0495(98)90184-6
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913–916. doi:10.4103/2230-8210.117215
   PubMedGoogle Scholar
• Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197(1):1–10. doi:10.1677/joe-07-0606
   PubMed Web of Science ®Google Scholar
• Löfberg E, Gutierrez A, Wernerman J, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest. 2002;32(5):345–353. doi:10.1046/j.1365-2362.2002.00993.x
   PubMed Web of Science ®Google Scholar
• Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin’s anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab. 2009;297(6):E1260–E1268. doi:10.1152/ajpendo.00345.2009
   PubMed Web of Science ®Google Scholar
• Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002;51(3):599–605. doi:10.2337/diabetes.51.3.599
   PubMed Web of Science ®Google Scholar
• Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 2014;43(1):75–102. doi:10.1016/j.ecl.2013.10.005
   PubMed Web of Science ®Google Scholar
• Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(Suppl 3):14–23. doi:10.1046/j.1365-2362.32.s3.3.x
   PubMed Web of Science ®Google Scholar
• Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11):1500–1510. doi:10.1016/j.metabol.2011.06.012
   PubMed Web of Science ®Google Scholar
• Fain JN. Effect of dibutyryl-3’,5’-AMP, theophylline and norepinephrine on lipolytic action of growth hormone and glucocorticoid in white fat cells. Endocrinology. 1968;82(4):825–830. doi:10.1210/endo-82-4-825
   PubMed Web of Science ®Google Scholar
• Ramshanker N, Jessen N, Voss TS, et al. Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. Metabolism. 2019;99:1–10. doi:10.1016/j.metabol.2019.06.013
   PubMed Web of Science ®Google Scholar
• Bilotta FL, Arcidiacono B, Messineo S, et al. Insulin and osteocalcin: further evidence for a mutual cross-talk. Endocrine. 2018;59(3):622–632. doi:10.1007/s12020-017-1396-0
   PubMed Web of Science ®Google Scholar
• Chen SM, Peng YJ, Wang CC, Su SL, Salter DM, Lee HS. Dexamethasone down-regulates osteocalcin in bone cells through leptin pathway. Int J Med Sci. 2018;15(5):507–516. doi:10.7150/ijms.21881
   PubMed Web of Science ®Google Scholar
• Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–469. doi:10.1016/j.cell.2007.05.047
   PubMed Web of Science ®Google Scholar
• Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017;132:1–8. doi:10.1016/j.bcp.2017.02.001
   PubMed Web of Science ®Google Scholar
• Mizokami A, Yasutake Y, Gao J, et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One. 2013;8(2):e57375. doi:10.1371/journal.pone.0057375
   PubMed Web of Science ®Google Scholar
• Mizokami A, Mukai S, Gao J, et al. GLP-1 signaling is required for improvement of glucose tolerance by osteocalcin. J Endocrinol. 2020;244(2):285–296. doi:10.1530/joe-19-0288
   PubMed Web of Science ®Google Scholar
• Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122(11):4172–4189. doi:10.1172/jci63377
   PubMed Web of Science ®Google Scholar
• Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav. 2012;106(3):387–393. doi:10.1016/j.physbeh.2011.12.001
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21(2):91–117. doi:10.1002/dmrr.538
   PubMed Web of Science ®Google Scholar
• Kappe C, Fransson L, Wolbert P, Ortsäter H. Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. Clin Sci. 2015;129(5):405–414. doi:10.1042/cs20140719
   Web of Science ®Google Scholar
• Jensen DH, Aaboe K, Henriksen JE, et al. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia. 2012;55(5):1406–1416. doi:10.1007/s00125-012-2459-7
   PubMed Web of Science ®Google Scholar
• Eriksen M, Jensen DH, Tribler S, Holst JJ, Madsbad S, Krarup T. Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia. 2015;58(5):920–928. doi:10.1007/s00125-015-3522-y
   PubMed Web of Science ®Google Scholar
• Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death. Diabetologia. 2012;55(4):1048–1057. doi:10.1007/s00125-011-2422-z
   PubMed Web of Science ®Google Scholar
• Linssen MM, van Raalte DH, Toonen EJ, et al. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal. 2011;23(11):1708–1715. doi:10.1016/j.cellsig.2011.06.002
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506. doi:10.1016/j.tem.2011.09.001
   PubMed Web of Science ®Google Scholar
• Rafacho A, Gonçalves-Neto LM, Santos-Silva JC, et al. Pancreatic alpha-cell dysfunction contributes to the disruption of glucose homeostasis and compensatory insulin hypersecretion in glucocorticoid-treated rats. PLoS One. 2014;9(4):e93531. doi:10.1371/journal.pone.0093531
   PubMed Web of Science ®Google Scholar
• Marco J, Calle C, Hedo JA, Villanueva ML. Enhanced glucagon secretion by pancreatic islets from prednisolone-treated mice. Diabetologia. 1976;12(4):307–311. doi:10.1007/bf00420973
   PubMed Web of Science ®Google Scholar
• van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81–93. doi:10.1111/j.1365-2362.2008.02067.x
   PubMed Web of Science ®Google Scholar
• Derrou S, Bouziane T, Salhi H, El Ouahabi H. Pheochromocytoma and glucoregulation disorders. Ann Afr Med. 2021;20(1):42–45. doi:10.4103/aam.aam_13_20
   PubMed Web of Science ®Google Scholar
• Hamaji M. Pancreatic alpha- and beta-cell function in pheochromocytoma. J Clin Endocrinol Metab. 1979;49(3):322–325. doi:10.1210/jcem-49-3-322
   PubMed Web of Science ®Google Scholar
• Komada H, Hirota Y, So A, et al. Insulin secretion and insulin sensitivity before and after surgical treatment of pheochromocytoma or paraganglioma. J Clin Endocrinol Metab. 2017;102(9):3400–3405. doi:10.1210/jc.2017-00357
   PubMed Web of Science ®Google Scholar
• Wiesner TD, Blüher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. J Clin Endocrinol Metab. 2003;88(8):3632–3636. doi:10.1210/jc.2003-030000
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Shikama H, Chu DT, Exton JH. Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle. J Clin Invest. 1981;68(3):706–713. doi:10.1172/jci110306
   PubMed Web of Science ®Google Scholar
• Harbeck B, Danneberg S, Rahvar AH, et al. Exploring the impact of short- and long-term hydrocortisone replacement on cognitive function, quality of life and catecholamine secretion: a pilot study. Appl Psychophysiol Biofeedback. 2016;41(3):341–347. doi:10.1007/s10484-016-9338-9
   PubMed Web of Science ®Google Scholar
• Zilberter T. Appetite, reward, and obesity: the causes and consequences of eating behaviors. Front Psychol. 2015;6:411. doi:10.3389/fpsyg.2015.00411
   PubMed Web of Science ®Google Scholar
• Perry RJ, Resch JM, Douglass AM, et al. Leptin’s hunger-suppressing effects are mediated by the hypothalamic-pituitary-adrenocortical axis in rodents. Proc Natl Acad Sci U S A. 2019;116(27):13670–13679. doi:10.1073/pnas.1901795116
   PubMed Web of Science ®Google Scholar
• Shimizu H, Arima H, Watanabe M, et al. Glucocorticoids increase neuropeptide Y and agouti-related peptide gene expression via adenosine monophosphate-activated protein kinase signaling in the arcuate nucleus of rats. Endocrinology. 2008;149(9):4544–4553. doi:10.1210/en.2008-0229
   PubMed Web of Science ®Google Scholar
• Xu J, Bartolome CL, Low CS, et al. Genetic identification of leptin neural circuits in energy and glucose homeostases. Nature. 2018;556(7702):505–509. doi:10.1038/s41586-018-0049-7
   PubMed Web of Science ®Google Scholar
• Ishida-Takahashi R, Uotani S, Abe T, et al. Rapid inhibition of leptin signaling by glucocorticoids in vitro and in vivo. J Biol Chem. 2004;279(19):19658–19664. doi:10.1074/jbc.M310864200
   PubMed Web of Science ®Google Scholar
• Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur J Endocrinol. 2014;170(2):311–319. doi:10.1530/eje-13-0754
   PubMed Web of Science ®Google Scholar
• Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007;61(3):580–584; discussion 584–585. doi:10.1227/01.Neu.0000290906.53685.79
   Web of Science ®Google Scholar
• Caretto A, Lanzi R, Piani C, Molgora M, Mortini P, Losa M. Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. Pituitary. 2017;20(5):553–560. doi:10.1007/s11102-017-0817-7
   PubMed Web of Science ®Google Scholar
• Ntali G, Capatina C, Grossman A, Karavitaki N. Clinical review: functioning gonadotroph adenomas. J Clin Endocrinol Metab. 2014;99(12):4423–4433. doi:10.1210/jc.2014-2362
   PubMed Web of Science ®Google Scholar
• Djerassi A, Coutifaris C, West VA, et al. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab. 1995;80(2):591–594. doi:10.1210/jcem.80.2.7852525
   PubMed Web of Science ®Google Scholar
• Banerjee AA, Mahale SD. Role of the extracellular and intracellular loops of follicle-stimulating hormone receptor in its function. Front Endocrinol. 2015;6:110. doi:10.3389/fendo.2015.00110
   PubMed Web of Science ®Google Scholar
• Liu XM, Chan HC, Ding GL, et al. FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway. Aging Cell. 2015;14(3):409–420. doi:10.1111/acel.12331
   PubMed Web of Science ®Google Scholar
• Onori P, Mancinelli R, Franchitto A, et al. Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. Liver Int. 2013;33(6):914–925. doi:10.1111/liv.12177
   PubMed Web of Science ®Google Scholar
• Song Y, Wang ES, Xing LL, et al. Follicle-stimulating hormone induces postmenopausal dyslipidemia through inhibiting hepatic cholesterol metabolism. J Clin Endocrinol Metab. 2016;101(1):254–263. doi:10.1210/jc.2015-2724
   PubMed Web of Science ®Google Scholar
• Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell. 2006;125(2):247–260. doi:10.1016/j.cell.2006.01.051
   PubMed Web of Science ®Google Scholar
• Qi X, Guo Y, Song Y, et al. Follicle-stimulating hormone enhances hepatic gluconeogenesis by GRK2-mediated AMPK hyperphosphorylation at Ser485 in mice. Diabetologia. 2018;61(5):1180–1192. doi:10.1007/s00125-018-4562-x
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu M, Ipekci SH, Kebapcilar L, et al. Risk factors for diabetes mellitus in women with primary ovarian insufficiency. Biol Trace Elem Res. 2013;154(3):313–320. doi:10.1007/s12011-013-9738-0
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Chen Y, Du Y, Jin X, Zhang Z. Follicle stimulating hormone, its association with glucose and lipid metabolism during the menopausal transition. J Obstet Gynaecol Res. 2020;46(8):1419–1424. doi:10.1111/jog.14297
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER, Virtanen JK, Niskanen L, et al. Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women. Menopause. 2017;24(7):796–802. doi:10.1097/gme.0000000000000834
   PubMed Web of Science ®Google Scholar
• Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96(7):2178–2185. doi:10.1210/jc.2010-2959
   PubMed Web of Science ®Google Scholar
• Park SK, Harlow SD, Zheng H, et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet Med. 2017;34(4):531–538. doi:10.1111/dme.13301
   PubMed Web of Science ®Google Scholar
• Young KA, Chaffin CL, Molskness TA, Stouffer RL. Controlled ovulation of the dominant follicle: a critical role for LH in the late follicular phase of the menstrual cycle. Hum Reprod. 2003;18(11):2257–2263. doi:10.1093/humrep/deg467
   PubMed Web of Science ®Google Scholar
• Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. 2017;232(2):R99–r113. doi:10.1530/joe-16-0405
   PubMed Web of Science ®Google Scholar
• Shorakae S, Ranasinha S, Abell S, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol. 2018;89(5):628–633. doi:10.1111/cen.13808
   PubMed Web of Science ®Google Scholar
• Li H, Zhang G, Guo Y, et al. Autoimmune activation of the GnRH receptor induces insulin resistance independent of obesity in a female rat model. Physiol Rep. 2021;8(24):e14672. doi:10.14814/phy2.14672
   PubMed Web of Science ®Google Scholar
• Eisner JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res. 2003;11(2):279–286. doi:10.1038/oby.2003.42
   PubMedGoogle Scholar
• Solano ME, Sander VA, Ho H, Motta AB, Arck PC. Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS). J Reprod Immunol. 2011;92(1–2):33–44. doi:10.1016/j.jri.2011.09.003
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li C, Zhang W, Zheng X, Chen X. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. J Med Food. 2020;23(4):375–387. doi:10.1089/jmf.2019.4580
   PubMed Web of Science ®Google Scholar
• Banaś M, Olszanecka-Glinianowicz M, Zahorska-Markiewicz B. Rola czynnika martwicy nowotworów i interleukiny-6 w zespole policystycznych jajników[The role of tumor necrosis factor and interleukin-6 in polycystic ovary syndrome]. Pol Merkur Lekarski. 2006;21(125):489–491. Polish.
   PubMedGoogle Scholar
• Zhou Y, Lv L, Liu Q, Song J. Total flavonoids extracted from Nervilia Fordii function in polycystic ovary syndrome through IL-6 mediated JAK2/STAT3 signaling pathway. Biosci Rep. 2019;39(1). doi:10.1042/bsr20181380
   Google Scholar
• Beck-Peccoz P, Giavoli C, Lania AA. 2019 update on TSH-secreting pituitary adenomas. J Endocrinol Invest. 2019;42(12):1401–1406. doi:10.1007/s40618-019-01066-x
   PubMed Web of Science ®Google Scholar
• Yamada S, Fukuhara N, Horiguchi K, et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg. 2014;121(6):1462–1473. doi:10.3171/2014.7.Jns1471
   PubMed Web of Science ®Google Scholar
• Li Y, Wang L, Zhou L, et al. Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2. Mol Cell Endocrinol. 2017;446:70–80. doi:10.1016/j.mce.2017.02.015
   PubMed Web of Science ®Google Scholar
• Zhu P, Liu X, Mao X. Thyroid-stimulating hormone levels are positively associated with insulin resistance. Med Sci Monit. 2018;24:342–347. doi:10.12659/msm.905774
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Zhao W, Zhu MY, Tang SS, Zhang H. Thyroid-stimulating hormone induces the secretion of tumor necrosis factor-α from 3T3-L1 adipocytes via a protein kinase A-dependent pathway. Exp Clin Endocrinol Diabetes. 2013;121(8):488–493. doi:10.1055/s-0033-1347266
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng L. Thyroid-stimulating hormone inhibits insulin receptor substrate-1 expression and tyrosyl phosphorylation in 3T3-L1 adipocytes by increasing NF-κB DNA-binding activity. Dis Markers. 2022;2022:7553670. doi:10.1155/2022/7553670
   PubMed Web of Science ®Google Scholar
• Del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol. 1999;276(5):E849–E855. doi:10.1152/ajpendo.1999.276.5.E849
   PubMedGoogle Scholar
• Weinstein SP, O’Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology. 1994;135(2):649–654. doi:10.1210/endo.135.2.8033812
   PubMed Web of Science ®Google Scholar
• Gierach M, Gierach J, Junik R. Insulin resistance and thyroid disorders. Endokrynol Pol. 2014;65(1):70–76. doi:10.5603/ep.2014.0010
   PubMed Web of Science ®Google Scholar
• Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol. 2000;14(7):947–955. doi:10.1210/mend.14.7.0470
   PubMedGoogle Scholar
• Dimitriadis G, Baker B, Marsh H, et al. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am J Physiol. 1985;248(5 Pt 1):E593–E601. doi:10.1152/ajpendo.1985.248.5.E593
   PubMedGoogle Scholar
• Lenzen S, Kücking H. Inhibition of insulin secretion by L-thyroxine and D-thyroxine treatment in rats under the influence of drugs affecting the adrenergic nervous system. Acta Endocrinol. 1982;100(4):527–533. doi:10.1530/acta.0.1000527
   PubMedGoogle Scholar
• Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5(9):1066–1070. doi:10.1038/12506
   PubMed Web of Science ®Google Scholar
• Butler AA, Kesterson RA, Khong K, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology. 2000;141(9):3518–3521. doi:10.1210/endo.141.9.7791
   PubMed Web of Science ®Google Scholar
• Hainer V, Aldhoon hainerová I, Kunešová M, Taxová Braunerová R, Zamrazilová H, Bendlová B. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R). Physiol Res. 2020;69(Suppl 2):S245–s254. doi:10.33549/physiolres.934512
   PubMedGoogle Scholar
• Girardet C, Butler AA. Neural melanocortin receptors in obesity and related metabolic disorders. Biochim Biophys Acta. 2014;1842(3):482–494. doi:10.1016/j.bbadis.2013.05.004
   PubMed Web of Science ®Google Scholar
• Schneeberger M, Gómez-Valadés AG, Altirriba J, et al. Reduced α-MSH Underlies Hypothalamic ER-Stress-Induced Hepatic Gluconeogenesis. Cell Rep. 2015;12(3):361–370. doi:10.1016/j.celrep.2015.06.041
   PubMed Web of Science ®Google Scholar
• Lee YS, Challis BG, Thompson DA, et al. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab. 2006;3(2):135–140. doi:10.1016/j.cmet.2006.01.006
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. doi:10.1038/nature05482
   PubMed Web of Science ®Google Scholar
• Lipton JM, Catania A, Ichiyama T. Marshaling the Anti-Inflammatory Influence of the Neuroimmunomodulator alpha-MSH. News Physiol Sci. 2000;15:192–195. doi:10.1152/physiologyonline.2000.15.4.192
   PubMedGoogle Scholar
• Hill C, Dunbar JC. The effects of acute and chronic alpha melanocyte stimulating hormone (alphaMSH) on cardiovascular dynamics in conscious rats. Peptides. 2002;23(9):1625–1630. doi:10.1016/s0196-9781(02)00103-1
   PubMed Web of Science ®Google Scholar
• Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol. 2003;59(4):492–499. doi:10.1046/j.1365-2265.2003.01876.x
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–1508. doi:10.1210/jc.2008-2332
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–3453. doi:10.1210/jc.2013-1771
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799. doi:10.1210/jc.2013-2480
   PubMed Web of Science ®Google Scholar
• Giustina A. Optimal use of pegvisomant in acromegaly: are we getting there? Endocrine. 2015;48(1):3–8. doi:10.1007/s12020-014-0462-0
   PubMed Web of Science ®Google Scholar
• Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res. 2016;48(5):299–305. doi:10.1055/s-0035-1569277
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A. Dopamine agonists: from the 1970s to today. Neuroendocrinology. 2019;109(1):34–41. doi:10.1159/000499470
   PubMed Web of Science ®Google Scholar
• Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485–534. doi:10.1210/er.2005-9998
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism. 1991;40(6):639–644. doi:10.1016/0026-0495(91)90057-4
   PubMed Web of Science ®Google Scholar
• Kamath V, Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20(11):1697–1701. doi:10.2337/diacare.20.11.1697
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154–1161. doi:10.2337/diacare.23.8.1154
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferrigno R, De Martino MC, et al. Medical treatment of Cushing’s disease: an overview of the current and recent clinical trials. Front Endocrinol. 2020;11:648. doi:10.3389/fendo.2020.00648
   PubMed Web of Science ®Google Scholar
• Gilis-Januszewska A, Bogusławska A, Rzepka E, Ziaja W, Hubalewska-Dydejczyk A. Individualized medical treatment options in Cushing disease. Front Endocrinol. 2022;13:1060884. doi:10.3389/fendo.2022.1060884
   PubMed Web of Science ®Google Scholar